Splash Beverage Group Azioni (AMEX: SBEV)

Ultime notizie per Splash Beverage Group (AMEX:SBEV) Azioni

Splash Beverage Group

Splash Beverage Group Inc is a portfolio company managing multiple brands across several growth segments within the consumer beverage industry. The company's two reportable operating segments are: (1) the manufacture and distribution of non-alcoholic and alcoholic beverages, and (2) the retail sale of beverages and groceries online. The company generates the majority of its revenue from the E-Commerce segment. Qplash is a wholly owned division of Splash. It is the company's first entry point into the e-commerce channel. For beverage-alcohol products, the company operate within what is referred to as a "Three Tier Distribution System" where manufacturers are not permitted to sell directly to retailers, but instead, contract for local and regional distribution with independent distributors.

Wells Fargo analyst Marc Torrente maintains Lamb Weston Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) with a Overweight and lowers the price target from $70 to $65.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Lamb Weston Hldgs, Lowers Price Target to $65

Wells Fargo analyst Marc Torrente maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Overweight and lowers the price target from $100 to $88.

FRPT

Wells Fargo Maintains Overweight on Freshpet, Lowers Price Target to $88

Wells Fargo analyst Colin Langan maintains Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) with a Equal-Weight and raises the price target from $305 to $364.

Wells Fargo Maintains Equal-Weight on Lithia Motors, Raises Price Target to $364

Empowering Semiconductor Manufacturers with Actionable Insight, Solution Advising, and Expert Knowledge Capture for Scalable Operations
SINGAPORE, July 9, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4464223-1&amp;h=1108924701&amp;u=https%3A%2F%2Fwww.kns.com%2F&amp;a=Kulicke%C2%A0and%C2%A0Soffa+Industries%2C%C2%A0Inc.%C2%A0">Kulicke&nbsp;and&nbsp;Soffa Industries,&nbsp;Inc.&nbsp;</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>) ("Kulicke &amp; Soffa", "K&amp;S", "we" or the "Company"), a global leader in semiconductor assembly solutions, and&nbsp;Lavorro Inc. ("Lavorro"), a pioneer in Generative AI for semiconductor manufacturing, announced today a strategic partnership to deliver next-generation smart manufacturing solutions. This collaboration aims to provide customers with actionable insights, expert-guided solution advice, and scalable knowledge reuse – enabling intelligent and data-driven guidance across the semiconductor value chain.

KLIC

Kulicke & Soffa And Lavorro Partner To Deliver AI-Powered Smart Manufacturing Solutions For Semiconductor Industry

Wells Fargo analyst Colin Langan maintains AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) with a Equal-Weight and raises the price target from $187 to $209.

Wells Fargo Maintains Equal-Weight on AutoNation, Raises Price Target to $209

Oppenheimer analyst Noah Kaye maintains Republic Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) with a Outperform and raises the price target from $262 to $268.

Oppenheimer Maintains Outperform on Republic Services, Raises Price Target to $268

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbioaffinitytech.com%2F&amp;esheet=54287611&amp;newsitemid=20250709031359&amp;lan=en-US&amp;anchor=bioAffinity+Technologies&amp;index=1&amp;md5=8fc7a46a9df7609adfdd4434d2f10cb3">bioAffinity Technologies</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>, BIAFW)),a biotechnology company addressingthe need for noninvasive, accurate tests for the detection of early-stage cancer, today released a new case study of a complex clinical case in which <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cypathlung.com&amp;esheet=54287611&amp;newsitemid=20250709031359&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=2&amp;md5=7d70a85863bfec3ba5924562e54f019d">CyPath&#xAE; Lung</a> identified Stage 1A adenocarcinoma lung cancer in a patient whose PET imaging and risk model probability indicated a low risk of malignancy.
"CyPath&#xAE; Lung gave us the critical data point we were missing. This patient had all the red flags – heavy tobacco use, COPD and a suspicious nodule – but imaging and risk calculators weren't enough for the patient to overcome her trepidation and to justify an invasive procedure. The CyPath&#xAE; Lung test result tipped the scale. Without it, we might have waited for the next annual CT scan, and we could have missed a Stage 1A lung cancer," said Gordon Downie, MD, PhD, bioAffinity Technologies' Chief Medical Officer. "Instead, CyPath&#xAE; Lung gave us the confidence to intervene surgically when everything else pointed in the direction of watchful waiting."
The patient, a 70-year-old female, was an active smoker with more than a 50 pack-year history and COPD. In April 2023, a low-dose CT scan revealed nodules in the right upper and middle lobes. A follow-up scan in December of that year showed improvement, including resolution of the 5mm nodule in the right upper lobe. But the December scan also revealed a new 3mm nodule in the fissure between the two lobes. Risk calculators placed the probability of malignancy at only 0.2%, and clinical guidelines recommended annual CT surveillance.
By February 2025, the fissure nodule had grown to 8mm, but a PET scan showed low uptake of the radioactive tracer, which is consistent with a benign outcome. Dr. Downie, who at the time was the Director of the Lung Nodule Clinic at Titus Regional Medical Center, ordered CyPath&#xAE; Lung for his patient. The test returned a positive result of 0.83, indicating a high probability of lung cancer. The patient subsequently quit smoking and underwent surgery to remove the nodule via wedge resection. Pathology confirmed Stage 1A adenocarcinoma.
"Each case study underscores the benefit of adding CyPath&#xAE; Lung to the standard of care for evaluating indeterminate lung nodules," bioAffinity Technologies' President and CEO Maria Zannes said. "CyPath&#xAE; Lung provides clarity when imaging and risk models are inconclusive and when other adjuvant diagnostics are contraindicated or simply fall short."

Biotech

General

BIAF

Bioaffinity Technologies Releases A New Case Study Of A Complex Clinical Case In Which Cypath Lung Identified Stage 1A Adenocarcinoma Lung Cancer In A Patient Whose Pet Imaging And Risk Model Probability Indicated A Low Risk Of Malignancy.

Wells Fargo analyst Chris Carey maintains Scotts Miracle Gro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) with a Overweight and raises the price target from $72 to $75.

Wells Fargo Maintains Overweight on Scotts Miracle Gro, Raises Price Target to $75

Additionally, the companies expanded their photovoltaic module R&amp;D collaboration focused on optimizing performance of utility-scale solar

FSLR

UbiQD Enters Into Exclusive Multi-Year Agreement To Supply Flourescent QD Technology To First Solar

<a href="https://www.theinformation.com/articles/layoffs-microsoft-tells-staff-invest-ai-skilling" title="https://www.theinformation.com/articles/layoffs-microsoft-tells-staff-invest-ai-skilling">https://www.theinformation.com/articles/layoffs-microsoft-tells-staff-invest-ai-skilling</a>

Management

MSFT

"After Layoffs, Microsoft Tells Staff to 'Invest in Your Own AI Skilling'" - The Information

Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma.
Through the acquisition of this <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">respiratory disease-focused</a> company, Merck will add Ohtuvayre (ensifentrine), a first-in-class, selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its cardiovascular and pulmonary pipeline and portfolio.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45692578/regeneron-sanofi-stock-falls-after-uneven-smokers-lung-drug-data" rel="noreferrer noopener">Regeneron, Sanofi Stock Falls After Uneven Smoker&#8217;s Lung Drug Data</a>
The U.S. Food and Drug Administration approved Ohtuvayre in June 2024 for the maintenance treatment of chronic obstructive pulmonary <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39526177/first-inhaled-copd-therapy-in-over-2-decades-fda-approves-verona-pharmas-first-commercial-product" rel="noreferrer noopener">disease (COPD) in adult patients</a>.
Ohtuvayre is the first novel inhaled mechanism for COPD in more than 20 years, combining bronchodilator and non-steroidal anti-inflammatory effects.
Ohtuvayre is also being evaluated in clinical trials for non-cystic fibrosis bronchiectasis.
The transaction is expected to close in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46314549/merck-to-acquire-verona-pharma-expanding-its-portfolio-to-include-ohtuvayre-ensifentrine-a-first-i" rel="noreferrer noopener">fourth quarter of 2025</a> and will result in the capitalization of most of the purchase price as an intangible asset for Ohtuvayre.
The Financial Times, which <a href="https://www.ft.com/content/bf1c2253-15b3-426a-975d-15ddca1d84a5" target="_blank" rel="noreferrer noopener">first</a> reported the possible takeover, added that the deal would be Merck's biggest since it bought Prometheus Biosciences <a href="https://www.benzinga.com/markets/equities/23/04/31825415/merck-acquires-prometheus-biosciences-for-10-8b-strengthening-its-immunology-pipeline" target="_blank" rel="noreferrer noopener">for $10.8 billion in 2023</a>.
It reflects a growing trend of big drug companies acquiring biotech firms that already have approved, revenue-generating products, as they seek to replace revenue from major drugs losing patent protection.
The FT report states that Merck's cancer treatment Keytruda, the world's top-selling drug with nearly $30 billion in annual revenue, is set to come off patent and face U.S. government price-setting rules as early as 2028.
Since Rob Davis became Merck's CEO in April 2021, the company has been one of the most active in the pharmaceutical industry in terms of acquisitions and licensing, with the highest deal count and spending. However, investors have been pushing for even more deals in recent months to help offset the expected decline in sales once Keytruda loses patent protection.
The FT report highlighted that Davis was seeking deals worth between $1 billion and $15 billion, or even more, if the opportunity was right.
Earlier this year, Merck signed a licensing agreement worth up to $2.2 billion with China&#8217;s Jiangsu Hengrui Pharmaceuticals for the global rights <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44477157/merck-partners-with-hengrui-pharma-in-177-billion-deal-for-cardiovascular-treatment" rel="noreferrer noopener">to a heart disease drug</a>.
According to a July media report, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) was reportedly in talks with Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) about a partnership worth <a target="_blank" href="https://www.benzinga.com/news/contracts/25/07/46249640/astrazeneca-in-15b-talks-for-drug-that-could-upend-lung-cancer-treatment" rel="noreferrer noopener">up to $15 billion.</a>
Price Action: VRNA stock rose 20.7% to $104.83. MRK stock was up 0.50% at $81.78 during the premarket session at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46314112/super-micro-accelerates-european-footprint-to-meet-exploding-ai-needs" target="_blank" rel="noreferrer noopener">Super Micro Accelerates European Footprint To Meet Exploding AI Needs</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

Movers

Trading Ideas

SMMT

VRNA

Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug

Xometry, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>), <a href="https://www.globenewswire.com/Tracker?data=_pyOLr0majw1g1m9gutZ3rVaAJ7aj905qOBvgYiBEISpBaUTm0HY9xfRkIN-KgVNrWEQhHjQXe1EMPAkgECj10vRfam6-DfSva9KcC5wMDk-NSKesLtJlHmqZCuYqijN">the global AI-powered marketplace</a> connecting enterprise buyers with suppliers of manufacturing services, announced the launch of its Teamspace solution in <a href="https://www.globenewswire.com/Tracker?data=puyd7bPIIqv4eLNlMXcHOuEBOG6l60URl-A9u50gHoB25ymOUAEmpU8R0Oal99u7laymUZ-6P9Ie61u5S-unl5ASuF6AXLb0WsNXtCMctIo=">Europe</a>, <a href="https://www.globenewswire.com/Tracker?data=uOX5NHpD-xglwjBpayP22zCE7G7D1mGaowCXA-W2DNJywLLUvBXw9vGkqNjOpwZt3O4gRLBPidjQHDcfHgE5qg==">UK</a> and <a href="https://www.globenewswire.com/Tracker?data=1BBNvEUZmrGGSvPK1rHruYzH7xjXtH6p82jVTbh0weoNDDczOGKJaoFoScywq9Q-sLelyMVjXtRRX-82JG90k9VbnOqDHPYPqarM80Ks0oU=">Turkey</a>. Teamspace is a cloud-based solution within the Xometry platform that enables customers to collaborate with other users on projects and custom part orders.
Additionally, the Teamspace solution in Europe, UK and Turkey includes:
<ul>
<li>Real-time visibility and control over orders: All team members see shared quoting activity and order history, which supports repeat ordering, transparency, and accountability.</li>
<li>Personalized user notifications: Users can configure individual alerts for updates on quotes, order shipments, payments, and invoices – ensuring no critical step is missed.</li>
<li>Designed to boost operational efficiency for enterprises: Especially useful for distributed teams managing high-volume and complex custom part orders.</li>
</ul>

XMTR

Xometry Launches Teamspace Solution In Europe, UK And Turkey

INVO Fertility Announces 'Improved' INVOcell Pricing To Make It More Affordable

Wells Fargo analyst Christopher Carey maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Equal-Weight and raises the price target from $60 to $90.

Wells Fargo Maintains Equal-Weight on Estee Lauder Cos, Raises Price Target to $90

Connect Biopharma Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the Company's collaborator and exclusive licensee in China, Simcere Pharmaceutical Co., Ltd. ("Simcere"), has submitted its New Drug Application for rademikibart to the National Medical Products Administration of China ("NMPA") for the treatment of atopic dermatitis ("AD") in adults and adolescents.
"Simcere continues to make strong progress in advancing rademikibart in China, our potentially best in class next generation IL-4Rα antibody," said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. "Atopic dermatitis remains a large and growing market in China, and rademikibart has the potential to significantly improve the condition for millions of patients. Together, we remain committed to advancing rademikibart for the treatment of a range of inflammatory diseases including AD, asthma, and chronic obstructive pulmonary disease."
In 2023, Connect and Simcere entered into an exclusive license and collaboration agreement for rademikibart in China. Under the agreement, Simcere was granted exclusive rights to develop, manufacture, and commercialize rademikibart for all indications in Greater China, including mainland China, Hong Kong, Macau, and Taiwan, while Connect retains rights in all other markets.
As part of the agreement, Connect is eligible to receive milestone payments up to an aggregate remaining amount of approximately $110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China. The AD market in China represents considerable opportunity, with an estimated 70 million patients with AD.

CNTB

Connect Biopharma Holdings Announces Company's Collaborator And Exclusive Licensee in China, Simcere Pharmaceutical Has Submitted Its New Drug Application For Rademikibart To The National Medical Products Administration Of China For The Treatment Of Atopic Dermatitis

Entry to Canada will come as generic semaglutide hits the market for the first time, marking a major step in expanding access to affordable weight loss care
Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) the leading digital health and wellness platform, today announced its plans to bring its affordable, holistic weight loss program to Canada, timed with the anticipated first-ever availability of generic semaglutide anywhere in the world. This move follows the recent closing of the company's acquisition of ZAVA, the pioneering digital health platform in Europe.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Plans To Bring Holistic Weight Loss Program To Canada, Timed With Anticipated Availability Of Generic Semaglutide Anywhere In World, Following ZAVA Acquisition Completion

NTHI

Globe NewswireNeOnc Technologies Holdings Joins Russell Microcap Index

Wells Fargo analyst Chris Carey maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Equal-Weight and lowers the price target from $142 to $135.

Wells Fargo Maintains Equal-Weight on Clorox, Lowers Price Target to $135

Oppenheimer analyst Jason Helfstein maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) with a Outperform and raises the price target from $200 to $220.

GOOG

GOOGL

Oppenheimer Maintains Outperform on Alphabet, Raises Price Target to $220

Wells Fargo analyst Chris Carey maintains Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) with a Equal-Weight and lowers the price target from $65 to $60.

Comments

Splash Beverage Group

Notizie

Ultime notizie per Splash Beverage Group (AMEX:SBEV) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO